A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

July 26, 2021

Study Completion Date

July 26, 2021

Conditions

Healthy Participants

Interventions

DRUG

PF-06842874

Single dose administration of PF-06842874

DRUG

Placebo

Single dose administration of placebo

DRUG

Relative Bioavailability

Relative bioavailability assessment of modified-release formulation

Trial Locations (2)

New Haven Clinical Research Unit, New Haven

Pfizer New Haven Clinical Research Unit, New Haven